5:46 PM
 | 
Feb 21, 2014
 |  BC Extra  |  Top Story

Isis jumps on interim SMA data

RNAi play Isis Pharmaceuticals Inc. (NASDAQ:ISIS) added $920.5 million in market cap on Friday after reporting top-line data from a Phase Ib/IIa trial evaluating the company's ISIS-SMNRx to treat spinal muscular atrophy (SMA) in patients ages 2-15. In 24 patients in the first three...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >